Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry
(CAMEO Trial)
Recruiting in Palo Alto (17 mi)
+11 other locations
Overseen ByTracy Wang, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Chiesi USA, Inc.
No Placebo Group
Trial Summary
What is the purpose of this trial?The purpose of this registry is to address optimal platelet inhibition during the early management of MI patients prior to coronary angiography or CABG.
Eligibility Criteria
Inclusion Criteria
For the first 50 patients at each participating site, consecutive patients are entered in the registry if they are ≥ 18 years of age, underwent coronary angiography for a STEMI or NSTEMI, and received cangrelor at any time during the hospitalization or an oral P2Y12 inhibitor during his/her first 48 hours of the hospitalization for MI.
The patient received cangrelor at any time during his/her hospitalization for MI.
The patient received a P2Y12 inhibitor and an opiate/opioid within 24 hours prior to or during primary PCI for STEMI presentation.
+3 more
Participant Groups
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Washington UniversitySt. Louis, MO
Kootenai Hospital District dba Kootenai HealthCoeur d'Alene, ID
Henry Ford Health SystemDetroit, MI
Washington UniversitySaint Louis, MO
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Chiesi USA, Inc.Lead Sponsor
Duke UniversityCollaborator